SXTP 60 Degrees Pharmaceuticals Inc. Quick Ratio

The visualization of 60 Degrees Pharmaceuticals (SXTP) market price on the GURU.Markets platform demonstrates a quick ratio of 1.74. Company management is effectively optimizing R&D costs and transparently reporting on drug trials. The business relies on global alliances to combat tropical diseases; however, a limited product portfolio and costly marketing are creating financial pressure on 60 Degrees Pharmaceuticals (SXTP).

SXTP: 60degreespharma.com Intermediate Coverage Ratio 02/21/2024 - 10/29/2026

Comprehensive metric breakdowns and analytics for 60 Degrees Pharmaceuticals (SXTP)

- market value and analyst target forecast:

Price Chart 60degreespharma.com|SXTP - Consensus Target

- market capitalization data:

Market Capitalization 60 Degrees Pharma|SXTP - Enterprise Value

- balance sheet net asset value indicators:

Accounting Value per Share 60 Degrees Pharmaceuticals|SXTP - Accounting Value of Company|Market Capitalization to Book Value Ratio 60degreespharma.com|SXTP - Company Total Asset Base

- debt and liquidity data:

- earnings and valuation multiples information:

SXTP - Profit After Payment of Taxes

General company analysis:60 Degrees Pharmaceuticals Inc. - SXTP

Manufactured product of 60 Degrees Pharmaceuticals

US government contracts for tropical infection drugs create a steady cash flow for 60 Degrees Pharmaceuticals (SXTP). Analyzing the acid-test ratio dynamics, an investor can see the company's ability to instantly settle obligations without liquidating inventory. This metric aggregates only cash and accounts receivable, excluding low-liquidity assets. The stability of this ratio confirms the financial resilience of a business protected by long-term patents and a monopoly position.

Analysis of competing companies